| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/22/2013 | EP2594551A1 Uses of pharmaceutical-grade ferric organic compounds |
| 05/22/2013 | EP2594318A1 Methods of facilitating cell survival using neurotrophin mimetics |
| 05/22/2013 | EP2594275A1 Prophylactic or therapeutic agent for diabetes |
| 05/22/2013 | EP2594274A1 Novel hyaluronic acid decomposition-promoting factor and inhibitor thereof |
| 05/22/2013 | EP2594273A1 Methods, compositions, and formulations for preventing or reducing adverse effects in a patient |
| 05/22/2013 | EP2594272A2 Aerosolized fluoroquinolones and uses thereof |
| 05/22/2013 | EP2594271A1 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid for the treatment of psoriasis. |
| 05/22/2013 | EP2594270A2 The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) |
| 05/22/2013 | EP2594269A1 Controlled release nucleated tablet |
| 05/22/2013 | EP2594268A1 Anti-angiogenic composition containing macrolactin a and a derivative thereof as active ingredients |
| 05/22/2013 | EP2594267A1 Protective Agent for Retinal Nerve or Optic Nerve |
| 05/22/2013 | EP2594266A1 Pharmaceutical solid compositions containing ibuprofen salts |
| 05/22/2013 | EP2594265A1 Ca ix-specific inhibitors |
| 05/22/2013 | EP2594264A1 Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective rtk inhibitors |
| 05/22/2013 | EP2594263A2 Patch for treating and alleviating symptoms of skin diseases accompanied by effusion of blood proteins |
| 05/22/2013 | EP2594262A1 Substrate of three-layer structure and water-containing adhesive patch including same |
| 05/22/2013 | EP2594261A1 Composition for transdermal administration of rivastigmine |
| 05/22/2013 | EP2594260A1 Solid preparations comprising sirolimus with desired bioavailability and method for its preparation |
| 05/22/2013 | EP2594258A1 Oral gel comprising praziquantel |
| 05/22/2013 | EP2594141A1 Composition for protection against cell-damaging effects |
| 05/22/2013 | EP2593570A2 Fermented soya based mixture comprising isoflavones- aglicones, equol and lunasil, process for the preparation and uses thereof in food, medical and cosmetic fields |
| 05/22/2013 | EP2593547A2 Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg |
| 05/22/2013 | EP2593466A2 Bovine milk oligosaccharides |
| 05/22/2013 | EP2593462A1 NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS |
| 05/22/2013 | EP2593461A1 Compounds for the reduction of beta-amyloid production |
| 05/22/2013 | EP2593460A1 7, 9-nitrogen radical-4-oxo-4h-pyrido[l,2-a]pyrimidine-2-carboxylic acid benzylamide anti-virals |
| 05/22/2013 | EP2593459A1 Process for the preparation of organic salts |
| 05/22/2013 | EP2593458A1 Bicyclic pyrimidines |
| 05/22/2013 | EP2593457A1 Pyrazolo [1, 5a]pyrimidine and thieno [3, 2b]pyrimidine derivatives as irak4 modulators |
| 05/22/2013 | EP2593455A1 Purine compounds selective for i3 p110 delta, and methods of use |
| 05/22/2013 | EP2593454A1 New azacyclic compounds |
| 05/22/2013 | EP2593453A1 Azaindazole compounds |
| 05/22/2013 | EP2593452A1 Ip receptor agonist heterocyclic compounds |
| 05/22/2013 | EP2593451A2 Substituted imidazo[1,2-a]pyrimidines and -pyridines |
| 05/22/2013 | EP2593450A1 Substituted imidazoquinoline derivatives as kinase inhibitors |
| 05/22/2013 | EP2593448A1 New cristalline forms of n-[2-[[(2,3-difluoropheny)methyl)thio]-6-{[(1r,2s)-2,3- dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide |
| 05/22/2013 | EP2593443A2 Process and assembly for producing alkylene oxides and glycol ethers |
| 05/22/2013 | EP2593439A2 Process for preparing antiviral compounds |
| 05/22/2013 | EP2593435A1 Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives |
| 05/22/2013 | EP2593434A1 Pyridine compounds as sodium channel blockers |
| 05/22/2013 | EP2593433A2 N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels |
| 05/22/2013 | EP2593432A1 N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors |
| 05/22/2013 | EP2593431A2 Chemical compounds |
| 05/22/2013 | EP2593430A1 Derivatives of 1,4-dihydropyridine possessing antiviral efficacy |
| 05/22/2013 | EP2593428A2 N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels |
| 05/22/2013 | EP2593425A1 Therapeutically active compositions and their method of use |
| 05/22/2013 | EP2593277A2 Novel fused pyrazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
| 05/22/2013 | EP2593139A2 Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer |
| 05/22/2013 | EP2593121A2 THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF |
| 05/22/2013 | EP2593113A1 Cell therapy |
| 05/22/2013 | EP2593112A2 Novel antibacterial compounds, methods of making them, and uses thereof |
| 05/22/2013 | EP2593111A2 New compounds for treating cancer and other diseases |
| 05/22/2013 | EP2593110A1 Treatment of lung infections by administration of tobramycin by aerolisation |
| 05/22/2013 | EP2593109A1 Method and formulations for treating sialic acid deficiencies |
| 05/22/2013 | EP2593108A2 Pharmaceutical compositions comprising r(+) budesonide and one or more bronchodilators |
| 05/22/2013 | EP2593107A1 Tyrosine kinase inhibitors |
| 05/22/2013 | EP2593106A1 Organic compounds |
| 05/22/2013 | EP2593105A1 Palatable pharmaceutical composition comprising vx-950 |
| 05/22/2013 | EP2593104A2 Methods of treating and preventing/reducing the likelihood of mesial temporal lobe epilepsy (tle) |
| 05/22/2013 | EP2593103A2 Reducing transmission of sexually transmitted infections |
| 05/22/2013 | EP2593102A1 Oxazole derivatives useful as modulators of faah |
| 05/22/2013 | EP2593101A2 Combination therapy using a ruthenium complex |
| 05/22/2013 | EP2593100A2 Method of treating refractory cancer |
| 05/22/2013 | EP2593099A1 Wogonin for the prevention and therapy of cardiac hypertrophy |
| 05/22/2013 | EP2593098A2 Methods and compositions for cancer immunotherapy |
| 05/22/2013 | EP2593097A1 Compounds with a skin pigmenting activity and pharmaceutical or cosmetic compositions containing them |
| 05/22/2013 | EP2593096A2 Diclofenac salt of tramadol |
| 05/22/2013 | EP2593095A1 (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof |
| 05/22/2013 | EP2593094A1 Aqueous composition comprising bromhexine |
| 05/22/2013 | EP2593093A1 Use of a cationic amphiphilic drug for the preparation of a formulation for the reduction of subcutaneous adipose tissue |
| 05/22/2013 | EP2593092A2 Oral administration forms for controlled release of rifampicin or other antibiotics for the treatment of bacterial infections and inflammatory diseases of the gastrointestinal tract |
| 05/22/2013 | EP2593091A1 C-met modulator pharmaceutical compositions |
| 05/22/2013 | EP2593090A1 C-met modulator pharmaceutical compositions |
| 05/22/2013 | EP2593089A1 Solid dispersion of alfa-ketoamide derivatives |
| 05/22/2013 | EP2593087A1 Parenteral formulations of elacytarabine derivatives |
| 05/22/2013 | EP2593086A1 Lipid bilayer carrier for drugs or imaging agents |
| 05/22/2013 | EP2593085A1 Dual drug delivery using silicone gels |
| 05/22/2013 | EP2593083A2 Eudermic compositions |
| 05/22/2013 | EP2593082A1 Biodegradable nano-, meso-, and micro-polymer particles for maintaining a low surface tension in the lung and for protecting the pulmonary surfactant |
| 05/22/2013 | EP2592951A1 Nutraceutical composition obtained from fungus-challenged soy seedlings |
| 05/22/2013 | EP2592950A1 Isomaltulose for use in enhancing mental performance |
| 05/22/2013 | EP2592934A1 Novel dihydropyridin-2(1h)-one compounds as s-nitrosoglutathione reductase inhibitors and neurokinin-3 receptor antagonists |
| 05/22/2013 | EP2592933A1 Mif inhibitors and their uses |
| 05/22/2013 | EP2592932A2 Novel tetrahydropyrazolo[3,4-b]azepine derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
| 05/22/2013 | EP2086535B1 Angiotensin ii receptor antagonist for the treatment of systemic diseases in cats |
| 05/22/2013 | CN1729012B Composition for treating solid tumors |
| 05/22/2013 | CN1655673B Methods and compositions for treating ectoparasite infestation |
| 05/22/2013 | CN1652754B Tasted masked veterinary solid compositions |
| 05/22/2013 | CN103119166A Prophylactic or therapeutic agent for fibrosis |
| 05/22/2013 | CN103119068A Hybrid cooperative complexes of hyaluronic acid |
| 05/22/2013 | CN103119063A Recombinant antibody structures binding to and blocking the activity of vascular endothelial growth factor 2 (VEGFR- 2 /KDR) |
| 05/22/2013 | CN103119047A Tricyclic proteasome activity enhancing compounds |
| 05/22/2013 | CN103119045A Pyrrolopyrimidine compounds and uses thereof |
| 05/22/2013 | CN103119043A Fused heterocyclic compound and application thereof |
| 05/22/2013 | CN103119042A Novel heterocyclic compound, and composition for treating inflammatory diseases using same |
| 05/22/2013 | CN103119041A Paxillin stimulating compositions and cosmetic uses thereof |
| 05/22/2013 | CN103119039A Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response |
| 05/22/2013 | CN103119038A 4 - (5 - isoxazolyl or 5 - pyrrazolyl -1,2,4- oxadiazol - 3 - yl) -mandelic acid amides as sphingosin- 1 - phosphate 1 rreceptor agonists |
| 05/22/2013 | CN103119037A Phenylquinazoline derivatives |
| 05/22/2013 | CN103119035A Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |